OasisLMS

Drug induced liver injury (DILI) remains one of the most challenging and unpredictable forms of hepatic disease, largely due to marked patient to patient variability in susceptibility. The goal of this program is to propose an integrative pre clinical new approach methodologies (NAM) based research concept for human DILI, combining patient-derived and engineered human tissues using emerging technologies such as induced pluripotent stem cells, organoids, gene editing, and comprehensive genomics. By introducing population based organoid systems, this strategy may enable mechanistic studies of inter-individual susceptibility, accelerating the future of precision hepatotoxicology. This activity originally aired on March 12, 2026.

This activity will not offer CE credits.